

Boston Scientific

## **Boston Scientific Announces Japanese Approval for the TAXUS® Express2™ Stent System**

PRNewswire-FirstCall  
NATICK, Mass.  
(NYSE:BSX)

NATICK, Mass., April 3 /[PRNewswire-FirstCall](#)/ -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its TAXUS® Express2™ paclitaxel-eluting coronary stent system in Japan. The Company plans to launch the product after reimbursement approval is granted.

"The approval of the TAXUS Express2 stent is an important event for the treatment of cardiovascular disease in Japan," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "We are pleased to provide Japanese physicians with this proven technology, which will help improve the quality of life for so many patients."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: <http://www.bostonscientific.com/>.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

CONTACT: Paul Donovan  
508-650-8541 (office)  
508-667-5165 (mobile)  
Media Relations  
Boston Scientific Corporation

Dan Brennan  
508-650-8538 (office)  
617-459-2703 (mobile)  
Investor Relations  
Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Paul Donovan, Media Relations, +1-508-650-8541, mobile: +1-508-667-5165, or Dan Brennan, Investor Relations, +1-508-650-8538, mobile: +1-617-459-2703, both of Boston Scientific Corporation

Web site: <http://www.bostonscientific.com/>

---

<https://news.bostonscientific.com/news-releases?item=58954>